Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Evolus has a “Moderate Buy” consensus rating from six analysts: four recommend buying, one recommends holding, and one recommends selling. The average 12-month price target is $14.50.
• EOLS recently traded at $8.32, near its 52-week high of $8.69, with its 50-day and 200-day moving averages at $6.82 and $5.77, respectively.
• Institutional investors and hedge funds own approximately 90.69% of Evolus shares, with several firms recently increasing or initiating positions.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $14.50.

Several research firms have recently issued reports on EOLS. Weiss Ratings raised Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, June 15th. BTIG Research restated a "buy" rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Finally, Wall Street Zen upgraded shares of Evolus from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th.

Evolus Price Performance

EOLS traded down $0.07 during trading on Monday, reaching $8.32. 26,553 shares of the stock were exchanged, compared to its average volume of 1,026,594. The company has a market capitalization of $549.67 million, a price-to-earnings ratio of -16.00 and a beta of 1.35. Evolus has a 1 year low of $3.86 and a 1 year high of $8.69. The business's 50 day moving average price is $6.82 and its two-hundred day moving average price is $5.77.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Larson Financial Group LLC grew its holdings in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company's stock valued at $33,000 after buying an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Evolus in the fourth quarter valued at $34,000. Wexford Capital LP purchased a new stake in shares of Evolus in the third quarter valued at $37,000. California State Teachers Retirement System boosted its stake in shares of Evolus by 79.9% during the second quarter. California State Teachers Retirement System now owns 5,455 shares of the company's stock valued at $38,000 after acquiring an additional 2,423 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Evolus during the second quarter valued at $40,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source